

					
						November 25, 2017 - By Henry Gaston
Robert Pohly decreased its stake in Hdfc Bank Ltd (HDB) by 22.82% based on its latest 2017Q2 regulatory filing with the SEC. Samlyn Capital Llc sold 196,500 shares as the company’s stock rose 20.33% with the market. The hedge fund run by Robert Pohly held 664,500 shares of the commercial banks company at the end of 2017Q2, valued at $57.79 million, down from 861,000 at the end of the previous reported quarter. Samlyn Capital Llc who had been investing in Hdfc Bank Ltd for a number of months, seems to be less bullish one the $74.48 billion market cap company. The stock increased 0.52% or $0.51 on November 24, reaching $98.43. About 185,785 shares traded. HDFC Bank Limited (ADR) (NYSE:HDB) has risen 36.23% since November 25, 2016 and is uptrending. It has outperformed by 19.53% the S&P500.Susquehanna International Group Llp increased its stake in Portola Pharmaceuticals Inc (Call) (PTLA) by 73.37% based on its latest 2017Q2 regulatory filing with the SEC. Susquehanna International Group Llp bought 183,800 shares as the company’s stock rose 22.73% with the market. The institutional investor held 434,300 shares of the health care company at the end of 2017Q2, valued at $24.40 million, up from 250,500 at the end of the previous reported quarter. Susquehanna International Group Llp who had been investing in Portola Pharmaceuticals Inc (Call) for a number of months, seems to be bullish on the $3.25B market cap company. The stock decreased 1.40% or $0.72 on November 24, reaching $50.55. About 330,613 shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since November 25, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.Since May 31, 2017, it had 1 insider buy, and 1 sale for $54.68 million activity. 119,442 shares were bought by BIRD JEFFREY W, worth $3.80M on Wednesday, May 31.Susquehanna International Group Llp, which manages about $227.60 billion US Long portfolio, decreased its stake in F5 Networks Inc (Call) (NASDAQ:FFIV) by 10,400 shares to 169,500 shares, valued at $21.54 million in 2017Q2, according to the filing. It also reduced its holding in Servisfirst Bancshares Inc (NASDAQ:SFBS) by 9,328 shares in the quarter, leaving it with 10,772 shares, and cut its stake in Lifepoint Health Inc (Put) (NASDAQ:LPNT). Investors sentiment decreased to 1.31 in 2017 Q2. Its down 0.29, from 1.6 in 2017Q1. It fall, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Guggenheim Limited Liability Corp holds 86,149 shares. First Tru Advsrs LP holds 0.01% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 70,858 shares. Rhenman Prns Asset Ab reported 0.89% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Blue Jay Cap Management Ltd Com holds 4.59% or 120,000 shares. The Illinois-based One Trading Limited Partnership has invested 0.04% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Public Employees Retirement Association Of Colorado owns 12,033 shares for 0% of their portfolio. Sphera Funds Mngmt invested in 0.38% or 40,000 shares. Proshare Advisors Ltd Com invested in 0.02% or 34,848 shares. California State Teachers Retirement Systems stated it has 88,055 shares. 5,645 were reported by Chicago Equity Prtnrs Ltd. Citadel Limited Co reported 0.02% stake. Vanguard Group Incorporated Incorporated accumulated 4.60M shares. Valley National Advisers has invested 0.03% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Perceptive Advsrs Limited Company, a New York-based fund reported 7,870 shares. Susquehanna International Gru Ltd Liability Partnership holds 0% or 46,749 shares in its portfolio.More notable recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Nasdaq.com which released: “Partner Fund Management, LP Buys Portola Pharmaceuticals Inc, Centene Corp …” on November 16, 2017, also Globenewswire.com with their article: “Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on …” published on November 07, 2017, Seekingalpha.com published: “Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?” on November 07, 2017. More interesting news about Portola Pharmaceuticals Inc (NASDAQ:PTLA) were released by: Globenewswire.com and their article: “Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch” published on November 21, 2017 as well as Livetradingnews.com‘s news article titled: “Portola Pharmaceuticals Inc (NASDAQ:PTLA) Bullish Divergence” with publication date: November 22, 2017.Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals had 28 analyst reports since August 5, 2015 according to SRatingsIntel. Credit Suisse maintained it with “Hold” rating and $7000 target in Thursday, August 10 report. Cowen & Co maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Wednesday, August 9 with “Buy” rating. Citigroup downgraded Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Friday, August 19 to “Neutral” rating. Credit Suisse maintained the stock with “Buy” rating in Wednesday, September 20 report. The stock has “Buy” rating by Citigroup on Monday, June 26. On Wednesday, August 5 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Buy” rating by Oppenheimer on Sunday, July 23. The firm has “Neutral” rating given on Monday, March 28 by Goldman Sachs. Morgan Stanley maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Friday, August 19. Morgan Stanley has “Overweight” rating and $28 target. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Outperform” rating by Oppenheimer on Friday, February 24.Among 3 analysts covering HDFC Bank Limited (NYSE:HDB), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. HDFC Bank Limited had 5 analyst reports since August 27, 2015 according to SRatingsIntel. Goldman Sachs maintained the stock with “Buy” rating in Wednesday, September 14 report. The firm earned “Hold” rating on Thursday, August 27 by Zacks. Zacks upgraded the shares of HDB in report on Monday, September 21 to “Hold” rating. The stock of HDFC Bank Limited (ADR) (NYSE:HDB) has “Sell” rating given on Wednesday, September 2 by Zacks. As per Tuesday, March 21, the company rating was downgraded by Morgan Stanley.Samlyn Capital Llc, which manages about $7.24 billion and $4.10B US Long portfolio, upped its stake in Nevro Corp by 21,609 shares to 68,800 shares, valued at $5.12 million in 2017Q2, according to the filing. It also increased its holding in Sensata Technologies Hldg Nv (NYSE:ST) by 421,401 shares in the quarter, for a total of 536,401 shares, and has risen its stake in Intra Cellular Therapies Inc (NASDAQ:ITCI). Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
